Cell proliferation and differentiation are highly coordinated during normal development. Many tumor cells exhibit both uncontrolled proliferation and a block to terminal differentiation. To understand the mechanisms coordinating these two processes, we have investigated the relation between cyclin-dependent kinase (CDK) activities and the block to differentiation in murine erythroleukemia (MEL) cells. We found that CDK6 (but not CDK4) is rapidly downregulated as MEL cells are induced to reenter erythroid differentiation and that maintenance of CDK6 (but not CDK4) activity by transfection blocks differentiation. Moreover, we found that PU.1, an Ets transcription factor that is oncogenic in erythroid cells and also can block their differentiation, controls the synthesis of CDK6 mRNA. These results suggest a mechanism for coupling proliferation and the block to differentiation in these leukemic cells through the action of an oncogenic transcription factor (PU.1) on a key cell cycle regulator (CDK6). Our findings suggest that studying the relative roles of CDK6 and CDK4 in other types of malignant cells will be important in designing approaches for cell cycle inhibition and differentiation therapy in cancer.
Introduction
Studies in many cell types have shown that proliferation and differentiation are inversely correlated processes during normal development. The fact that many cancers exhibit both loss of normal proliferation controls and properties of immature cells because of a block in completing differentiation also supports the existence of such an inverse relation. The molecular mechanisms underlying the coordination of cell proliferation and differentiation in both normal and malignant cells are just beginning to be understood (for a recent review see Zhu and Skoultchi (2001) ). Leukemic cells offer an attractive opportunity to investigate this relation because they often arise because of a single or a small number of genetic events leading to alterations in the structure or regulation of transcription factors that participate in normal blood cell differentiation (Look, 1997; Tenen et al., 1997) . Furthermore, some leukemic cell lines can be reprogrammed in vitro to undergo terminal differentiation (Rifkind et al., 1996) with accompanying changes in the proliferative status of the cells. Such cell systems may reveal new insights into the relation between cell cycle regulators and the transcription factors that control differentiation programs.
Friend virus-induced erythroleukemias of mice give rise to permanent cell lines of transformed erythroid precursor cells that are blocked at about the proerythroblast stage of differentiation (Marks et al., 1987) . Treatment of these murine erythroleukemia (MEL) cell lines with a variety of agents causes them to reinitiate erythroid differentiation culminating in the synthesis of hemoglobin and other red cell-specific proteins, terminal cell divisions and loss of tumorigenicity (Marks et al., 1987) . A central molecule in both the generation of erythroleukemias and their block to differentiation, as well as the in vitro reprogramming of MEL cells to resume erythroid differentiation is the transcription factor PU.1. PU.1 is a hematopoietic-specific Ets family transcription factor, which is required for development of the monocytic, granulocytic and B lymphoid lineages (Scott et al., 1994; McKercher et al., 1996) . It is not required for red blood cell differentiation. Deregulated expression of PU.1 in erythroid precursors, caused by proviral insertion at the Spi-1 locus encoding PU.1, is a key event in Friend virus-induced erythroleukemia (Moreau-Gachelin et al., 1988; Paul et al., 1989) . Binding of PU.1 to Gata-1, the erythroid-specific transcription factor that is required for red blood cell development, causes repression of Gata-1 (10-12), blocking erythroid differentiation in MEL cells (Rekhtman et al., 1999; Zhang et al., 1999; Nerlov et al., 2000) . Downregulation of PU.1, leading to release of Gata-1 repression, is required for reinitiation of differentiation by MEL cells (Rao et al., 1997; Rekhtman et al., 1999) . Whereas, the role of PU.1 in blocking differentiation in erythroleukemia is now better understood, its role in promoting proliferation in the leukemic cells has not been explored.
Proliferation of mammalian cells is primarily governed by the activities of a family of serine/threonine protein kinases called cyclin-dependent kinases (CDKs) (Ekholm and Reed, 2000) . Progression through the G1-phase is controlled by the activities of CDK4 and CDK6, which associate with the D-cyclins (D1, D2 and D3), and CDK2, which associates first with cyclin E and then later in S phase with cyclin A (Steinman, 2002) . Whereas functional differences are known among the D-, E-, and A-dependent kinases, differences between the two cyclin D-dependent kinases, CDK4 and CDK6, have not been reported. We recently reported that the activities of CDK4 and CDK6 are differentially regulated during reprogramming of MEL cells to terminal differentiation. We also showed that the activity of CDK4 (along with CDK2), but not CDK6, is crucial for the proliferation of MEL cells during the late stages of differentiation, once the cells have already been reprogrammed (Matushansky et al., 2000a) . Here we show that CDK6, but not CDK4, participates in the earlier reprogramming decision. Downregulation of CDK6, like downregulation of PU.1, is required for MEL cells to reinitiate differentiation. Furthermore, we present evidence that CDK6 gene transcription is regulated by PU.1.
Results

Differential regulation of CDK4 and CDK6 during commitment of erythroleukemia cells to terminal differentiation
Treatment of MEL cells with chemical inducers of differentiation such as dimethylsulfoxide (DMSO) leads initially to the production of cells that are not overtly differentiated but that are irreversibly committed to differentiate (Gusella et al., 1976) . The committed cells no longer require the presence of the inducer to execute the terminal differentiation program. Committed cells first appear 12-24 h after initiation of DMSO treatment and by 48 h most cells have become committed (Figure 1a) . After committing to differentiation, MEL cells continue to proliferate for several division cycles while accumulating hemoglobin and other red cellspecific proteins and then they arrest (Gusella et al., 1976) .
The commitment step defines a transition from continuously dividing leukemic cells to cells that are able to proliferate only a limited number of cell cycles. To investigate possible involvement of cell cycle regulators in this transition, we assayed the levels and activities of the cyclin-dependent kinases CDK2, CDK4 and CDK6 during DMSO-induced differentiation. The activities of CDK2 and CDK4 are relatively constant during the commitment period (12-48 h) and until 72 h, and then they decline at later times as cells undergo terminal arrest (Figure 1b) . The late decline in CDK2 and CDK4 activities is not because of a decline in the amounts of the catalytic subunit of the enzymes (Figure 1c ) nor in the amounts of the cyclin regulatory subunits (Matushansky et al., 2000a) . We showed previously that this late decline in CDK2 and CDK4 activities is because of induction of several CDK inhibitors. We also showed that the decline of both activities is required for the terminal arrest (Matushansky et al., 2000a) . In contrast to the behavior of CDK2 and CDK4, the activity of CDK6 is downregulated much earlier, between 12 and 24 h of DMSO treatment, and it is maintained at very low levels Figure 1b ). Immunoblotting shows that the early decline in CDK6 activity is because of a decline in the level of the catalytic subunit ( Figure 1c ). Northern blotting experiments show that the decline in CDK6 protein levels is because of a decline in CDK6 mRNA levels ( Figure 1d ). These observations show that there is differential regulation of CDK4 and CDK6 during the period when MEL cells are becoming committed to terminal differentiation.
Downregulation of CDK6 is required for DMSO-induced commitment to terminal differentiation
The foregoing observations suggest that a decline in CDK6 may be involved in the DMSO-induced reprogramming of MEL cells to terminal differentiation. To investigate this possibility, we generated stable MEL cell transfectants containing tetracycline-controlled expression vectors (Gossen et al., 1994) driving the synthesis of either CDK2, CDK4 or CDK6 as previously described (Matushansky et al., 2000a) . To distinguish the exogenous kinase activities from the endogenous murine kinases, we utilized vectors expressing human CDKs as fusion proteins containing a C-terminal HA tag. In addition, to avoid potential inhibition of CDK4 and CDK6 by INK4 CDK inhibitors, some of which are induced during MEL cell differentiation (Matushansky et al., 2000a) , we utilized mutant forms of CDK4 (Wolfel et al., 1995) and CDK6 (Grossel et al., 1999) , which are resistant to inhibition by the INK4 family. For each CDK, many transfectants were screened, and two transfectant clones were chosen that exhibited no detectable expression of the HA-tagged exogenous kinase in the absence of doxycycline and highly inducible expression with doxycycline ( Figure 2a ). To assess the activities of the exogenous CDKs and to compare their activities in the transfectants to that of endogenous CDKs, we performed in vitro kinase assays for each specific CDK using immunoprecipitation with specific antibodies in extracts from the transfected cells.
The specificity of the immunoprecipitation procedures used for the respective exogenous and endogenous CDKs was demonstrated by several results. First, no kinase activity was recovered in anti-HA immunoprecipitates of extracts from untransfected MEL cells ( Figure 2b , lanes 11 and 12 in each panel). Second, no CDK6 activity was recovered in anti-CDK6 immunoprecipitates of CDK6 transfectants that had been treated with DMSO. (Figure 2b lower panel, lanes 5 and 6.) This occurred because DMSO treatment leads to loss of endogenous CDK6. Similar results were obtained in anti-CDK2 and anti-CDK4 immunoprecipitates of transfectants treated for longer than 72 h with DMSO when the activities of these two endogenous kinases are lost (data not shown). Third, no kinase activity was recovered in anti-HA immunoprecipitates of extracts from transfectants that were not treated with doxycycline ( Figure 2b , lane 3 in each panel). However, abundant kinase activity was recovered from extracts of transfectants that were treated with doxycycline 1 and 9) . Similarly, abundant exogenous CDK2 and CDK4 kinase activities were seen in anti-HA immunoprecipitates of transfectants treated with both doxycycline and DMSO (Figure 2b upper and middle panels, lane 8). These results show that expression of the exogenous kinases can be maintained in differentiating cells.
To investigate the effects of exogenous kinases on the ability of MEL cells to differentiate, cells were cultured in the presence or absence of doxycycline for 24 h before initiating DMSO treatment. Then the production of hemoglobinized cells was measured at each day of DMSO treatment by benzidine staining. Figure 3 shows that induction of benzidine-positive cells by DMSO is almost completely inhibited by doxycycline treatment of CDK6 transfectants. This effect is strictly dependent upon treatment with doxycycline. The effect is also specific for CDK6 because treatment of CDK2 or CDK4 transfectants with doxycycline did not affect the rate of production of benzidine-positive cells by DMSO. Similar results were obtained using the plasma clot assay to measure the production of cells irreversibly committed to differentiate (data not shown). We conclude that the early decline in endogenous CDK6 induced by DMSO treatment is necessary for MEL cells to re-enter their terminal differentiation program.
CDK6 gene expression is regulated by the PU.1 transcription factor
The foregoing results indicate that downregulation of CDK6 is an early event required for the reprogramming of MEL cells to terminal differentiation. Another early event that is also required for MEL cell differentiation is downregulation of the PU.1 transcription factor (Rao et al., 1997; Rekhtman et al., 1999) . Thus, expression of either exogenous CDK6 or PU.1, at levels comparable to that in undifferentiated MEL cells, blocks terminal differentiation. Since downregulation of CDK6 appears to occur at the transcriptional level (Figure 1d) , we investigated a possible relation between PU.1 and CDK6 gene expression. First, we utilized MEL cell transfectants that constitutively express exogenous PU.1 (Rao et al., 1997) . Unlike untransfected MEL cells that downregulate PU.1 levels when treated with DMSO (Figure 4a ), these transfectants maintain PU.1 levels during DMSO treatment (Figure 4b) . As a consequence, the transfectants fail to commit to terminal differentiation (Rao et al., 1997) . In contrast to untransfected MEL cells that rapidly downregulate CDK6 activity upon DMSO treatment (Figure 1b) , we found that the CDK6 level is maintained in the PU.1 transfectants following DMSO treatment (Figure 4c) . Furthermore, kinase assays showed that, unlike DMSO-treated MEL cells, CDK6 activity is maintained in the PU.1 transfectants during DMSO treatment (Figure 4d) . Similar results were obtained with another PU.1 transfected MEL cell clone (data not shown). Thus, CDK6 levels are regulated in some way by PU.1.
To determine whether PU.1 regulation of CDK6 levels is a direct effect, or simply because of a failure of PU.1 transfectants to undergo differentiation, we prepared MEL cell transfectants expressing a conditionally active form of PU.1, achieved by fusing the human PU.1 coding sequence to the ligand binding domain of the human estrogen receptor (ER) (Nerlov and Graf, 1998) . The PU.1/ER fusion protein was constitutively expressed in transfectants under the direction of the EF1ppromoter in the pEBB expression vector (Rao  et al., 1997) . The PU.1/ER fusion protein is activated for (Nerlov and Graf, 1998) . To assay the effect of the PU.1/ER fusion protein on CDK6 levels, we first treated the transfectants with DMSO for 24 h to reduce the level of CDK6. The cells were then incubated for an additional 24 h in DMSO and estrogen and then assayed for CDK6 levels by immunoblotting. Activation of PU.1/ER led to a marked increase in CDK6 protein level (Figure 5a ). The advantage of using the PU.1/ER fusion protein is that direct effects of the PU.1 transcription factor on specific gene transcription can be distinguished from secondary effects by including a protein synthesis inhibitor, such as cycloheximide, along with estrogen in the inducing media (Grandori et al., 1996) . To determine whether the CDK6 gene is a direct target of PU.1, we treated PU.1/ER transfected cells for 24 h with DMSO to reduce the level of CDK6 mRNA (Figure 1d) . During the last 12 h of this treatment, cycloheximide was added at a concentration that inhibits at least 95% of cellular protein synthesis in MEL cells (Levenson and Housman, 1979) . Then cells were cultured with and without estrogen for various times and the levels of CDK6 mRNA were measured by Northern blotting. As controls for these experiments, we utilized a MEL cell line transfected with a GATA-1/ER fusion protein and untransfected MEL cells. Figure 5b shows that activation of the PU.1/ER fusion protein by estrogen led to a rapid induction of CDK6 mRNA. This effect is specific for PU.1/ER, as it was not seen in a GATA-1/ER transfectant nor untransfected MEL cells treated with estrogen. We conclude that CDK6 levels in MEL cells are very likely controlled by a direct effect of PU.1 on transcription of the CDK6 gene.
Discussion
A key finding in the work reported here is the observation that CDK6, but not CDK4, has the capacity to block DMSO-induced re-entry of MEL cells into their terminal differentiation program. To date, functional differences between these 2 cyclin D-dependent kinases have not been reported in other systems. The differential activity of CDK6 and CDK4 in blocking MEL cell differentiation is consistent with several of our other findings: (1) CDK6 activity and protein levels are downregulated during the early stages of MEL cell differentiation when the decision to differentiate is made, whereas CDK4 activity does not decline until very late (Figure 1 ) when several CDK inhibitors are induced and the cells undergo terminal arrest (Matushansky et al., 2000a) . We also observed similar differential regulation of CDK6 and CDK4 in primary mouse erythroblasts undergoing differentiation in response to erythropoietin (Hsieh et al., 2000) . (2) Enforced differentiation of MEL cells by chemical and natural CDK inhibitors requires specific inhibition of CDK6 (Matushansky et al., 2000b) . (3) DMSO for 12 h. Cycloheximide at a final concentration of 7.5 mg/ ml was added to the cultures and incubation was continued for an additional 12 h. Then each culture was separated into two aliquots and the aliquots were incubated further in the absence (ÀEst) or presence of ( þ Est) of 17b-estradiol. Total RNA was prepared at the indicated times and analysed by Northern blotting for CDK6 RNA levels as described in Materials and methods
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delay in final cell cycle withdrawal, resulting in extended proliferation of already committed, differentiating MEL cells (Matushansky et al., 2000a) . A previous study (Kiyokawa et al., 1994) found that overexpression of CDK4 could partially block MEL cell differentiation, but the abilities of CDK4 and CDK6 to block differentiation were not compared. However, in this previous study exogenous CDK4 was expressed at much higher levels than endogenous CDK4. In contrast, we expressed both exogenous kinases at levels similar to the endogenous kinases. It may be that at very high levels CDK4 can phosphorylate the important CDK6 substrate proteins required for blocking MEL cell differentiation.
The data presented here, as well as our earlier findings, suggest that CDK6 and CDK4 function at different stages of erythroid differentiation. CDK6 may participate with CDK2 in controlling proliferation at early stages, and CDK4 at later stages. This certainly is the case in MEL cells, as we reported previously that inhibition of CDK4 had no effect on proliferation of the leukemic blasts, whereas inhibition of CDK6 inhibited blast proliferation (Matushansky et al., 2000b) . Currently, we do not understand the molecular basis for the different biological activities of CDK6 and CDK4 in undifferentiated vs differentiating MEL cells. This could be based on a currently unrecognized preference of the two kinases for Rb or the related p107 and p130. Alternatively, other unknown substrates might be involved.
The findings reported here also suggest a mechanism by which the Friend virus-induced erythroleukemogenic process in mice causes both a block to differentiation and uncontrolled proliferation of leukemic erythroblasts. Inappropriate expression of PU.1 because of proviral insertion in erythroid precursors is a central event in the generation of these erythroleukemias (Moreau-Gachelin et al., 1988; Paul et al., 1989) . We reported previously that the block to differentiation imposed by PU.1 in these cells is because of its ability to bind directly to and inhibit the transcriptional activity of GATA-1, thereby preventing GATA-1 from promoting erythroid differentiation (Rekhtman et al., 1999) . Our observations showing that PU.1 regulates CDK6 levels, probably via transcriptional regulation of the CDK6 gene (Figures 4 and 5) , indicate that PU.1 also controls at least a part of the proliferation program in the leukemic cells. This view is also supported by the finding that PU.1 strongly stimulates the activity of the CDK6 promoter in transient transfections in heterologous cells (K Choe and AI Skoultchi, unpublished observations).
Our work might also suggest that CDK6 is a specific target for dysregulation in certain other types of malignant cells. There is circumstantial evidence linking CDK6 to leukemia and other cancers. Compared with CDK4, CDK6 is preferentially expressed in all hematopoietic cell types and exclusively expressed in some hematopoietic cells (Meyerson and Harlow, 1994; Della Ragione et al., 1997) . Translocations involving human chromosome 7q are the most common cytogenetic abnormalities in splenic lymphoma with villous lymphocytes, a leukemic variant of splenic marginal zone lymphoma, and in several patients the translocation breakpoints have been found to lie in the CDK6 promoter region (Corcoran et al., 1999) . CDK6 is the earliest CDK to be induced during human T-cell activation and high levels of CDK6 expression were found in 100% (N ¼ 25) of cases of T-cell lymphoblastic lymphoma/leukemia (T-LBL/ALL) (Chilosi et al., 1998) . Elevated levels of CDK6 also were reported in human squamous cell carcinomas (Timmermann et al., 1997) and in human neuroblastomas (Easton et al., 1998) and gliomas (Costello et al., 1997) . It will be important to investigate the relative roles of CDK6 and CDK4 in driving proliferation of other types of malignant cells, as well as in the corresponding normal cells at various stages of differentiation. Such information could prove to be very useful in designing strategies for modulating CDK activities in different tumor types (Senderowicz and Sausville, 2000) .
Materials and methods
Cell culture, differentiation and DNA transfection
Clone DS19 MEL cells were grown and differentiation was initiated as described previously (Rao et al., 1997; Rekhtman et al., 1999) . Stable MEL cell transfectants expressing doxycycline-inducible cell cycle regulators were generated by transfecting MEL cell clone C2 that stably expresses the reverse tetracycline-controlled transactivator rtTA (Gossen et al., 1994) with either pUHD CDK2-HA, CDK4R24C-HA and CD6R31C-HA as previously described (Matushansky et al., 2000a) . Stable MEL cell transfectants expressing PU.1/ ER were generated by cotransfecting MEL cells with pEBB PU.1/ER and pPGK-puro. The degree of differentiation was measured at various times by staining for the presence of hemoglobin with the benzidine reagent as described previously (Rao et al., 1997; Rekhtman et al., 1999) . A minimum of 100 cells or colonies was scored for each determination of cell differentiation.
Plasmids cDNAs encoding human CDK2-HA (a generous gift from L Zhu, Albert Einstein College of Medicine, Bronx, NY, USA), human CDK4R24C-HA and human CDK6R31C-HA (generous gifts of D Franklin and Y Xiong, University of North Carolina, Chapel Hill, NC, USA) were cloned into pUHD 10-3 as previously described (Matushansky et al., 2000a) . cDNA encoding PU.1/ER (Nerlov and Graf, 1998 ) (a generous gift of C Nerlov, Cytogenetic Laboratory, University Hospital of Copenhagen, Copenhagen, Denmark and T Graf, Albert Einstein College of Medicine, Bronx, NY, USA) was cloned into pCDNA-I. The plasmid was digested with BamHI and NotI. The released 1.8 kDa fragment encoding PU.1/ER was then cloned into the BamHI-NotI sites of the expression vector pEBB, previously linked to pPGK puro (Rao et al., 1997; Rekhtman et al., 1999) .
Antibodies
Immunoblot analysis was performed with polyclonal human specific (non-mouse cross-reactive) a-CDK2 (CalBiochem AB-1, PC44); polyclonal human a-CDK2 (a gift of Y Xiong); polyclonal human a-CDK4 (C-22) and a-CDK6 (C-21) (both from Santa Cruz Biotechnology). HRP-conjugated anti-mouse Immunoprecipitation-kinase analysis assays used purified polyclonal human a-CDK2, a-CDK4, a-CDK6 (gifts of Y Xiong) and polyclonal human a-CDK4 and a-CDK6 (gifts from M Pagano).
Immunoblot
Assays were performed on 100 mg of total protein extract as described previously (Matushansky et al., 2000a) .
Immunoprecipitation-kinase assays
Assays were performed on 100 mg (for CDK2) or 1000 mg (for CDK4 and CDK6) of total protein extract as described previously (Matushansky et al., 2000a) .
Northern blot analysis
Assays were performed on 10 mg of total cellular RNA isolated by the hot-phenol method as described previously (Rao et al., 1997) .
